Elsevier

Metabolism

Volume 85, August 2018, Pages 325-339
Metabolism

Review
The role of central dopamine and serotonin in human obesity: lessons learned from molecular neuroimaging studies

https://doi.org/10.1016/j.metabol.2017.09.007Get rights and content

Abstract

Obesity results from an imbalance between energy intake and expenditure, and many studies have aimed to determine why obese individuals continue to (over)consume food under conditions of caloric excess. The two major “neurotransmitter hypotheses” of obesity state that increased food intake is partially driven by decreased dopamine-mediated reward and decreased serotonin-mediated homeostatic feedback in response to food intake. Using molecular neuroimaging studies to visualize and quantify aspects of the central dopamine and serotonin systems in vivo, recent PET and SPECT studies have also implicated alterations in these systems in human obesity. The interpretation of these data, however, is more complex than it may appear. Here, we discuss important characteristics and limitations of current radiotracer methods and use this framework to comprehensively review the available human data on central dopamine and serotonin in obesity. On the basis of the available evidence, we conclude that obesity is associated with decreased central dopaminergic and serotonergic signaling and that future research, especially in long-term follow-up and interventional settings, is needed to advance our understanding of the neuronal pathophysiology of obesity in humans.

Introduction

Obesity now affects over 600 million adults worldwide [1]. It is associated with numerous cardiometabolic complications and forms a major threat to public health [2]. Obesity is caused by an imbalance between energy intake and expenditure. Its major driver is the persistent overconsumption of nutrients [3]. In this regard, it is highly relevant to determine why obese individuals continue to overconsume food under conditions where homeostatic needs have already been met.

Feeding behavior is mainly regulated by homeostatic and hedonic systems. The homeostatic system is primarily located in the hypothalamus and brainstem [4]. It receives and integrates input on energy availability from multiple peripheral organs and brain regions, and it adjusts food intake to balance energy availability and expenditure [5]. This system is closely connected to the hedonic system, which is involved in the motivational and rewarding aspects of food intake [6]. The striatum, one of the nuclei in the subcortical basal ganglia, has been identified as the center of the hedonic system [7]. This region can be subdivided in a ventral part, which includes the nucleus accumbens, and a dorsal part, which includes parts of the caudate nucleus and putamen [8]. For recent reviews of the numerous neural circuits that control food intake, we refer to Ferrario et al. [9] and Schwartz and Zeltser [10].

The neurotransmitters dopamine and serotonin fulfill important roles in hedonic and homeostatic signaling, respectively, but other neurotransmitters are also involved [11], [12]. Numerous studies, in rodents and humans [13], [14], [15], [16], have shown that experimental stimulation or inhibition of dopaminergic and serotonergic signaling is associated with changes in feeding behavior, motivation to eat, (food-related) reward learning, and energy expenditure. On the basis of these and other observations, it has been hypothesized that disturbed feeding behavior in obesity is caused by alterations in central dopamine and serotonin systems [16], [17]. Several neurotransmitter-related hypotheses have been generated to explain caloric overconsumption: i) the reward deficiency hypothesis states that food intake is increased to compensate for a diminished reward effect of food consumption due to decreased dopaminergic activity [18], and ii) the homeostatic hypothesis states that decreased hypothalamic serotonin signaling contributes to the overconsumption of food due to dysregulated homeostatic regulation [19].

Whereas animal studies have greatly enhanced our understanding of the neuronal pathophysiology of obesity (for reviews, see la Fleur and Serlie [20], Berthoud et al. [21], and Tulloch et al. [22]), it remains largely unknown how these paradigms translate to human obesity. In vivo molecular neuroimaging techniques provide attractive means to study the central dopamine and serotonin systems in human subjects, but seemingly conflicting results complicate the interpretation of the available data. Here, we aimed to comprehensively review the outcomes of neuroimaging studies on the regulation of food intake and body weight in humans. To this end, we will discuss current imaging methods, give an overview of the available evidence from human trials, and use this framework to explore how the data fit in with the major hypotheses of disturbed feeding behavior in human obesity.

Section snippets

Literature Search and Review Methods

We searched for relevant peer-reviewed English-language publications in the MEDLINE library (www.ncbi.nlm.nih.gov/pubmed) from inception through 24 August 2017. The literature search was focused on serotonin, dopamine, obesity, and related terms. We manually reviewed reference lists of selected articles for additional publications. Entries identified through the search were screened for relevance, and full-text articles were retrieved for in-depth review and methodological quality assessment.

Imaging of the Central Dopamine and Serotonin System

Methods to directly measure concentrations of dopamine and serotonin in the human brain are currently not available, but neuroimaging techniques have enabled us to assess markers of dopamine and serotonin signaling in vivo. With the use of radiopharmaceuticals (that is, radiotracers) and positron emission tomography (PET) or single photon emission computed tomography (SPECT), several dopamine and serotonin receptors and/or transporters can be visualized and quantified in the brain. Most studies

Results on Dopamine Receptors

Several studies have evaluated central D2R and D3R availability in relation to obesity (Table 3). Back in 2001, Wang et al. [18] reported for the first time that morbidly obese subjects have decreased striatal D2/3R BP. This has since been replicated in studies of morbidly obese subjects (BMI > 40 kg/m2) [35], [42], but other studies have not found such differences between lean and overweight/obese subjects [37], [38], [39]. In fact, two studies have found increased striatal D2/3R BP in obese

Changes in Phasic Dopamine Release

So far, we have focused on alterations in the tonic dopamine and serotonin release in obese subjects (that is, baseline imaging, without an active intervention). Physiologically, dopamine is released from the ventroanterior midbrain (substantia nigra and ventral tegmental area) to the striatum in a phasic manner in response to stimuli [71]. In rodents, dopamine release occurs after food cues, taste, consumption, and gut-brain signals [72], [73]. Some of these mechanisms have been translated to

Effects on the Dopamine System

Few longitudinal studies have assessed the effects of weight loss or gain on the cerebral dopamine system. Early after bariatric surgery (~ six weeks; ~ 15 kg lost), one study reported no change in striatal D2/3R BP [55], whereas one other study reported an increase in striatal D2/3R BP and another study reported a decrease in striatal D2/3R BP [37], [84]. These were small studies (five to 18 participants), and there were differences, among others, in operation techniques and neuroimaging methods,

Perspective

Central dopamine and serotonin are important mediators of feeding behavior in physiology and obesity, but our understanding of the role of these neurotransmitters in human obesity is limited. Current molecular neuroimaging technologies allow the spatial visualization and quantification of the receptors and transporters that are involved in central dopamine and serotonin systems, providing us with an attractive method to assess aspects of these systems in vivo. However, we stress that direct in

Concluding Remarks

The available evidence from human neuroimaging trials indicate that obesity may be associated with decreased dopaminergic and serotonergic signaling. These observations support the two major neurotransmitter theories of disturbed feeding behavior in obesity, where increased reward-seeking and decreased homeostatic feedback contribute to overconsumption of palatable food. Nevertheless, the limited number of neuroimaging studies, relatively small sample sizes, and difficult interpretation of the

Author Contributions

KAvG performed the search and study selection; KAvG and KWtH drafted the manuscript; JB, SElF, and MJS revised the manuscript.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Disclosure Statement

The authors declare that there is no conflict of interest associated with the manuscript.

References (104)

  • H.R. Berthoud et al.

    Blaming the brain for obesity: integration of hedonic and homeostatic mechanisms

    Gastroenterology

    (2017)
  • A.J. Tulloch et al.

    Neural responses to macronutrients: hedonic and homeostatic mechanisms

    Gastroenterology

    (2015)
  • D.R. Sibley et al.

    Molecular biology of dopamine receptors

    Trends Pharmacol Sci

    (1992)
  • E.M. van der Zwaal et al.

    Striatal dopamine D2/3 receptor availability increases after long-term bariatric surgery-induced weight loss

    Eur Neuropsychopharmacol

    (2016)
  • L. Gunther et al.

    Effects of chronic citalopram treatment on 5-HT1A and 5-HT2A receptors in group- and isolation-housed mice

    Eur J Pharmacol

    (2008)
  • D.J. Heal et al.

    Intracerebroventricular administration of 5,7-dihydroxytryptamine to mice increases both head-twitch response and the number of cortical 5-HT2 receptors

    Neuropharmacology

    (1985)
  • E. van de Giessen et al.

    No association between striatal dopamine transporter binding and body mass index: a multi-center European study in healthy volunteers

    Neuroimage

    (2013)
  • F. Caravaggio et al.

    Ventral striatum binding of a dopamine D(2/3) receptor agonist but not antagonist predicts normal body mass index

    Biol Psychiatry

    (2015)
  • L.C. Dang et al.

    Associations between dopamine D2 receptor availability and BMI depend on age

    Neuroimage

    (2016)
  • A.K. Koskela et al.

    Serotonin transporter binding and acquired obesity — an imaging study of monozygotic twin pairs

    Physiol Behav

    (2008)
  • P.S. Chen et al.

    Correlation between body mass index and striatal dopamine transporter availability in healthy volunteers—a SPECT study

    Neuroimage

    (2008)
  • J.B. Savitz et al.

    Neuroreceptor imaging in depression

    Neurobiol Dis

    (2013)
  • D.M. Small et al.

    Feeding-induced dopamine release in dorsal striatum correlates with meal pleasantness ratings in healthy human volunteers

    Neuroimage

    (2003)
  • K.H. Adams et al.

    A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables

    Neuroimage

    (2004)
  • D. Erritzoe et al.

    Brain serotonin 2A receptor binding: relations to body mass index, tobacco and alcohol use

    Neuroimage

    (2009)
  • M.E. Haahr et al.

    Obesity is associated with high serotonin 4 receptor availability in the brain reward circuitry

    Neuroimage

    (2012)
  • D. Erritzoe et al.

    Cerebral serotonin transporter binding is inversely related to body mass index

    Neuroimage

    (2010)
  • L. Reneman et al.

    The acute and chronic effects of MDMA (“ecstasy”) on cortical 5-HT2A receptors in rat and human brain

    Neuropsychopharmacology

    (2002)
  • K.E. Koopman et al.

    Diet-induced changes in the lean brain: hypercaloric high-fat-high-sugar snacking decreases serotonin transporters in the human hypothalamic region

    Mol Metab

    (2013)
  • W. Schultz

    Getting formal with dopamine and reward

    Neuron

    (2002)
  • W. Han et al.

    Striatal dopamine links gastrointestinal rerouting to altered sweet appetite

    Cell Metab

    (2016)
  • C. Davis et al.

    Sensitivity to reward and body mass index (BMI): evidence for a non-linear relationship

    Appetite

    (2008)
  • K.S. Burger et al.

    A functional neuroimaging review of obesity, appetitive hormones and ingestive behavior

    Physiol Behav

    (2014)
  • J.P. Dunn et al.

    Decreased dopamine type 2 receptor availability after bariatric surgery: preliminary findings

    Brain Res

    (2010)
  • P.Z. Tan et al.

    Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent

    Nucl Med Biol

    (1999)
  • S. Oya et al.

    2-((2-((Dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): an improved serotonin transporter ligand

    Nucl Med Biol

    (2000)
  • WHO

    Fact sheet: obesity and overweight

  • S.M. Grundy

    Metabolic complications of obesity

    Endocrine

    (2000)
  • M.H. Donovan et al.

    Serotonin and the regulation of mammalian energy balance

    Front Neurosci

    (2013)
  • G.J. Morton et al.

    Central nervous system control of food intake and body weight

    Nature

    (2006)
  • G.J. Morton et al.

    Neurobiology of food intake in health and disease

    Nat Rev Neurosci

    (2014)
  • C.R. Ferrario et al.

    Homeostasis meets motivation in the battle to control food intake

    J Neurosci

    (2016)
  • G.J. Schwartz et al.

    Functional organization of neuronal and humoral signals regulating feeding behavior

    Annu Rev Nutr

    (2013)
  • M.W. Schwartz et al.

    Central nervous system control of food intake

    Nature

    (2000)
  • R.D. Palmiter

    Dopamine signaling in the dorsal striatum is essential for motivated behaviors: lessons from dopamine-deficient mice

    Ann N Y Acad Sci

    (2008)
  • J.C. Halford et al.

    Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity

    Curr Drug Targets

    (2005)
  • R.B. Innis et al.

    Consensus nomenclature for in vivo imaging of reversibly binding radioligands

    J Cereb Blood Flow Metab

    (2007)
  • J.S. Kumar et al.

    PET tracers for serotonin receptors and their applications

    Cent Nerv Syst Agents Med Chem

    (2014)
  • J.P. van Wieringen et al.

    Agonist high- and low-affinity states of dopamine D(2) receptors: methods of detection and clinical implications

    Naunyn Schmiedebergs Arch Pharmacol

    (2013)
  • L.M. Paterson et al.

    Measuring endogenous 5-HT release by emission tomography: promises and pitfalls

    J Cereb Blood Flow Metab

    (2010)
  • Cited by (83)

    View all citing articles on Scopus
    View full text